Tesamorelin

Also: TH9507, tesamorelin acetate, GHRH(1-44) analog, GRF analog, Egrifta (brand name)

Research PeptideLimitedCharacterized in peer-reviewed clinical and preclinical literature as a stabilized synthetic GHRH analog (TH9507). Mechanistic and pharmacological activity is documented, but findings derive largely from specific study populations and endpoints. Broader interpretation, regulatory status, and source/quality verification remain the responsibility of a human editor.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

Tesamorelin is a synthetic, stabilized analog of growth hormone-releasing hormone (GHRH) that is characterized in the research literature as an agonist at the pituitary GHRH receptor. In the mechanisms described, it is reported to act on the somatotropic axis, influencing the release of endogenous growth hormone and downstream signaling involving insulin-like growth factor 1 (IGF-1). It has been examined in both clinical and preclinical settings, but the available evidence is limited and requires careful interpretation due to population-specific study designs and translation constraints. This profile is provided for research and educational purposes only; it is not a recommendation for any human or animal use and makes no claim of safety or efficacy.

Mechanism as described in the literature

Tesamorelin is a synthetic analog of the first 44 amino acids of human growth hormone-releasing hormone (GHRH), modified to increase stability relative to the native peptide. In mechanisms described in the literature, it is reported to bind GHRH receptors on pituitary somatotroph cells and to stimulate the release of endogenous growth hormone, which in turn is described as influencing hepatic production of insulin-like growth factor 1 (IGF-1).

Because it is characterized as acting upstream on the pituitary rather than supplying growth hormone directly, it is generally framed as a secretagogue-type agent operating within existing physiological feedback loops. These characterizations are drawn from pharmacological and clinical studies and describe biological activity only; they do not establish that the compound is safe or effective for any particular outcome.

Research areas

GHRH receptor signaling and endogenous growth hormone release as described mechanistically
IGF-1 axis dynamics and somatotropic pathway pharmacology
Body composition and adipose tissue distribution as examined in specific clinical research populations
Metabolic and hepatic lipid parameters as measured in study populations
Exploratory cognitive and neurophysiological endpoints discussed in the literature

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is tesamorelin?+

It is described in the research literature as a synthetic, stabilized analog of growth hormone-releasing hormone (GHRH). Mechanistically it is characterized as an agonist at the pituitary GHRH receptor. This is a neutral description of a research compound, not a recommendation for use.

Is tesamorelin the same as growth hormone?+

No. According to the mechanisms described, it is characterized as acting upstream on the pituitary GHRH receptor rather than supplying growth hormone directly, and is generally framed as a secretagogue-type agent that works within existing physiological feedback loops.

What does the current evidence show?+

The literature includes both clinical and preclinical work, but the evidence is limited and population-specific, and interpretation requires care due to study design and translation constraints. No conclusions about safety, efficacy, or any health outcome are drawn here, and sources should be verified by a qualified editor.